Eligible subjects were healthy 55- to 89-day-old infants with a gestational age ≥37 weeks and a birth weight ≥2.5 kg. We excluded infants with allergy to the vaccine or vaccine components, significant infection in the past 7 days, fever in the past 3 days, or previous exposure to either disease caused by or vaccination against N. meningitidis (serogroups A, C, W-135, or Y), Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus, Haemophilus influenzae type B (Hib), pneumococcus, or hepatitis B virus (HBV). A birth vaccination against HBV was permitted.
MenACWY-CRM was prepared by extemporaneous mixing of the lyophilized MenA component with the liquid MenCWY component immediately before intramuscular (IM) injection to the right thigh. Each 0.5-mL dose contained 10 μg of MenA oligosaccharide and 5 μg each of oligosaccharides from MenC, MenW-135, and MenY conjugated to CRM197 (∼50 μg).14 Concomitant vaccines were administered either IM or subcutaneously to the left thigh, as appropriate. In subjects only receiving routine vaccines, Hib vaccine was administered IM to the right thigh as control for local reactogenicity at 2, 4, and 6 months of age, whereas pneumococcal conjugate vaccine (PCV7) served as control for the reactogenicity assessments at 12 months of age.
All subjects received routine vaccines as per the schedule in Figure 1. Concomitant vaccines given during this study were combined DTaP-HBV-IPV (Pediarix, GlaxoSmithKline, Rixensart, Belgium); DTaP booster (Infanrix, GlaxoSmithKline); Hib-TT (ActHIB, Sanofi Pasteur, Swiftwater, PA); PCV7 (Prevnar, Wyeth, Pearl River, NY); rotavirus vaccine (RotaTeq, Merck & Co., Whitehouse Station, NJ); MMRV (ProQuad, Merck & Co.) or measles, mumps, and rubella vaccine (M-M-R II, Merck & Co.) and varicella vaccine (Varivax, Merck & Co.); and HAV. This study was completed before the pneumococcal 13-valent conjugate vaccine was available.
We obtained serum samples before and 1 month after the infant series (at 2 and 7 months of age) and before and 1 month after the 12-month toddler dose (at 12 and 13 months of age). Functional antibodies to each meningococcal serogroup were measured by serum bactericidal assay using human complement (hSBA). Titers were reported as the reciprocal of the dilution resulting in ≥50% killing at T60 (60 minutes) compared with T0 of the test strain in question.17 We measured immunogenicity as the percentage of subjects with hSBA titers ≥8 against each serogroup 1 month after the fourth dose and by geometric mean titers (GMTs).18 We used enzyme-linked immunosorbent assays to evaluate seroresponses to diphtheria, tetanus, Hib, HBV, pneumococcal, and pertussis antigens (pertussis toxin, filamentous hemagglutinin, and pertactin) and assessed seroresponse to poliovirus using a viral neutralization assay.
Given the absence of a US-licensed comparator vaccine, the first coprimary end point was sufficiency of the immune response 1 month after 4 doses of MenACWY-CRM administered at 2, 4, 6, and 12 months of age. Sufficiency of the immune response was prespecified as met if the lower limit (LL) of the 95% confidence interval (CI) for the percentage of infants with hSBA titers ≥8 was ≥80% for serogroup A and ≥85% for C, W, and Y.
The second coprimary objective was to demonstrate superiority of the immune response after 4 doses of MenACWY-CRM administered at 2, 4, 6, and 12 months of age compared with 1 dose at 12 months of age. Superiority was met if the LL of the 2-sided 95% CI for the ratio of GMTs (GMT4-dose series/GMT12-month dose only) was >2.0. Superiority was assessed using analysis of variance, as previously described.14
Secondary immunogenicity endpoints included (1) immune response after 3 doses at 2, 4, and 6 months of age as measured by the percentage of subjects with hSBA titers ≥8 against each serogroup, (2) persistence of immune response at 12 months of age after 3 doses at 2, 4, and 6 months of age, and (3) effect of concomitant administration of MenACWY-CRM with all routine vaccines as measured after 3 doses at 2, 4, and 6 months of age and at 13 months of age for the pneumococcal conjugate booster.
To evaluate the immune response of concomitant vaccines, certain analyses were prespecified as key secondary objectives. We defined noninferiority as being met as follows: for diphtheria, tetanus, Hib, HBV, and PCV7 (through dose 3), noninferiority was achieved if the LL of the 95% CI for the differences in seroresponse rates to the concomitant antigen for the groups ([MenACWY-CRM plus routine vaccines] − [routine vaccines alone]) was >−10%. For poliovirus, the threshold was >−5%. For pertussis antigens, noninferiority was defined as a geometric mean concentration (GMC) ratio (GMCMenACWY-CRM + routine/GMCroutine vaccines alone) >0.67. We defined immunologic noninferiority for the fourth dose of PCV7 as met if the LL of the 2-sided 95% CI for the ratio of the GMCs (GMCMenACWY-CRM + routine/GMCroutine vaccines alone) was >0.50.
For safety evaluations, we solicited all local and systemic reactions up to 7 days after each vaccination. All adverse events (AE) that required an office or emergency room visit, resulted in premature withdrawal from the study, or were considered serious (SAE) were collected during the entire study period. Investigators assigned AE severity and assessed relationship to vaccination.
We calculated sample size based on the first coprimary objective, guided by previous phase II immunogenicity results,16 and determined that 150 subjects per group were needed. The sample size resulted in 92% power for the first coprimary end point and 93% power for the second coprimary end point, for an overall power of 86% for the study. The immunogenicity analysis was based on the per-protocol population, which included all subjects who received all appropriately timed vaccine doses, provided appropriately timed evaluable serum samples, and were without major protocol deviation. The safety cohort included all subjects who received at least 1 dose of vaccine and provided any safety data. No imputations were performed for missing data. Missing data did not contribute to the denominators in means and percentages.
We enrolled 1508 subjects who were randomized 2:1 to receive MenACWY-CRM coadministered with routine vaccines or routine vaccines only followed by MenACWY-CRM in the second year of life (Fig. 1). Of the 1508 enrolled subjects, 479 were enrolled into the immunogenicity cohort (320 randomized to receive 4 doses of MenACWY-CRM with routine vaccines; 159 to receive routine vaccines only followed by MenACWY-CRM at 12 and 15 months of age; Fig. 1A). The remaining 1029 were enrolled into the safety-only cohort (680 to receive 4 doses of MenACWY-CRM with routine vaccines; 349 to receive routine vaccines only followed by MenACWY-CRM in the second year of life; Fig. 1B). Enrollment began on March 29, 2007, and all follow-ups were completed by November 13, 2009. Subject demographics were similar between groups (Table 1). The majority of subjects were male and white. The major reason for discontinuation was withdrawal of informed consent (Fig. 1).
Immunogenicity analyses were performed on the per-protocol data set, which consisted of 323 subjects after the infant series (223 received MenACWY-CRM plus routine vaccines; 100 received routine vaccines only) and 267 subjects after the 4-dose series (183 received MenACWY-CRM plus routine vaccines; 84 received routine vaccines only). One month after the third dose of MenACWY-CRM, the percentage of subjects with hSBA titers ≥8 for serogroups A, C, W, and Y were 67%, 97%, 96%, and 96%, respectively; before the fourth dose at 12 months of age, these percentages decreased to 12%, 52%, 69%, and 60%, respectively (Fig. 2). One month after the fourth dose of MenACWY-CRM administered at 12 months of age, 100% of subjects achieved hSBA titers ≥8 against serogroups W-135 and Y, and 94% and 98% of subjects achieved this level against serogroups A and C, respectively (Fig. 2). The LL of the 2-sided 95% CIs exceeded the prespecified criteria, demonstrating that the first coprimary end point was achieved.
Individuals who received 4 doses of MenACWY-CRM achieved significantly higher GMTs than the group that received only 1 dose at 12 months (Fig. 2B). Subjects who received 4 doses achieved GMTs that were 4.5- to 38-fold higher than subjects who only received 1 dose at 12 months of age. The LL of the 95% CI for the ratio of GMTs was >2.0 for all serogroups (range, 3.0–24), demonstrating that the second coprimary end point was met.
In regard to the secondary end point of immune responses to routine vaccines administered concomitantly with MenACWY-CRM, 1 month after the primary infant series (at 7 months), seroresponse rates were noninferior for diphtheria, tetanus, HBV, Hib antigens and all poliovirus serotypes (Fig. 3A). For pertussis, noninferiority was demonstrated for all antigens using the primary comparator, GMC ratios (Fig. 3B), although noninferiority was narrowly missed for pertactin when using a secondary end point of seroresponse (LL 95% CI, −12%). Similarly, seroresponses 1 month after the primary infant series were noninferior for all pneumococcal serotypes except for PnC 6B (LL 95% CI, −14%; Fig. 3C). However, 1 month after the fourth PCV7 dose at 12 months of age, noninferiority was achieved for all PCV7 serotypes (Fig. 3D).
Of 1508 enrolled subjects, 1500 were exposed to at least 1 vaccination, provided follow-up safety data, and were included in the safety analysis. Within 7 days after the third dose (given at 6 months), rates of erythema and induration after MenACWY-CRM administration were similar to or lower than those after the comparator vaccine Hib administration; rates of erythema and induration were lower within 7 days after MenACWY-CRM than after PCV7 administration at 12 months of age (Table 2). The percentage of subjects who experienced solicited systemic reactions was similar between groups (Table 2). The most common systemic reactions were irritability and sleepiness. Rates of fever were low and similar between groups.
After 3 doses of MenACWY-CRM, the percentages of subjects experiencing any AEs were similar between subjects who received MenACWY-CRM with concomitant vaccines (75%) and those who received routine vaccination only (76%). After 4 doses of MenACWY-CRM, AEs were lower among subjects who received MenACWY-CRM with routine vaccination (55%) compared with those who received routine vaccines alone (62%). The types of AEs were generally similar between groups; the most commonly reported AEs were upper respiratory tract infections (34%–36%).
SAEs were reported with similar frequency among groups. Three SAEs were considered to be at least possibly related to vaccination, 2 of which resulted in withdrawal from the study: 1 subject was diagnosed with Kawasaki disease 29 days after the third dose of MenACWY-CRM and concomitant routine vaccines, and 1 subject had partial complex seizures 31 days after the second dose of MenACWY-CRM with concomitant routine vaccines. The third subject experienced 2 episodes of febrile convulsions 8 and 29 days after the third dose of MenACWY-CRM with concomitant routine vaccines. All 3 conditions resolved within 7 days of event onset. No deaths occurred.
This study demonstrates that a 4-dose series of MenACWY-CRM was highly immunogenic in young infants with 94% to 100% seroresponse rates for all 4 meningococcal serogroups. Furthermore, 4 doses of MenACWY-CRM were significantly more immunogenic than a single dose administered at 12 months of age. Taken together, these results indicate that vaccinating infants with 4 doses of MenACWY-CRM will provide significant protection against meningococcal serogroups A, C, W-135, and Y. In light of infants' high risk from invasive meningococcal disease, the findings from this study represent a major advance toward protecting vulnerable infant populations against meningococcal disease.
An important observation in this study was the finding that more than 96% of subjects had hSBA titers ≥8 against 3 serogroups (C, W-135, and Y) after 3 doses, with 52% to 69% maintaining hSBA titers ≥8 for these same serogroups before a fourth MenACWY-CRM dose at 12 months of age. Although future studies will be needed to assess long-term persistence of immunity beyond the fourth dose, the current study provides evidence that 3 doses administered at 2, 4, and 6 months of age confer substantial protection against 3 of the epidemiologically relevant serogroups in the United States during the first year of life.
The current findings support our previous phase II trial, indicating that the MenACWY-CRM vaccine is highly immunogenic in infants.15,16 Our results contrast with the results of a phase II meningococcal vaccine trial in which a quadrivalent polysaccharide vaccine conjugated to diphtheria toxoid demonstrated suboptimal immune responses in young infants.6 We hypothesize that these differences may be related to differential immunogenicity of the carrier proteins (CRM197 vs. diphtheria toxoid) or to other aspects of the conjugation chemistry and vaccine design, such as the chemical linkers employed, selective sizing of oligosaccharides, and the ratio of oligosaccharides to carrier molecules.19
Antibody seroresponses after the third dose of routine vaccines administered with and without MenACWY-CRM were noninferior for all concomitant vaccine antigens, with the exception of pneumococcal serotype 6B. However, the clinical relevance of this difference is unclear, as subsequent seroresponses were noninferior for 6B after the fourth dose. Similarly, as the main secondary end point of pertactin GMC ratios showed essentially no difference between the 2 groups, the clinical significance of the lower pertactin seroresponse in recipients of concomitant MenACWY-CRM is unclear. Taken together, we conclude that MenACWY-CRM may be given concomitantly with routine pediatric vaccines without substantial concern for clinically relevant immunologic interference.
MenACWY-CRM was well tolerated, with local reactogenicity similar to that seen after vaccination with the comparator vaccine Hib. Furthermore, the majority of systemic reactions after vaccination with MenACWY-CRM were mild to moderate and comparable to those noted after routine vaccines alone. Overall, these results indicate that MenACWY-CRM administered with routine vaccines was safe and well tolerated in infants.
MenACWY-CRM was highly immunogenic in infants, making MenACWY-CRM the first multivalent meningococcal vaccine that can be used in a 4-dose primary immunization series from 2 months of age to offer protection against these 4 meningococcal serotypes. The use of MenACWY-CRM in young infants offers a powerful public health tool for reducing the burden of meningococcal sepsis and meningitis caused by serotypes A, C, W, and Y in infants.
Kathleen Jenks, PhD, and Lisa DeTora, PhD, provided assistance with the manuscript preparation. Susan E. Myers, MSc, and Gerard P. Johnson, PhD, of Complete Healthcare Communications, Inc., whose work was funded by Novartis Vaccines and Diagnostics, also assisted with the manuscript preparation.
US Investigators: Marsha Anderson, Henry Bernstein, Stan L. Block Jr, John L. Buttler, Archana Chatterjee, Shane Glade Christensen, Blaise Congeni, Matthew J. Cornish, Marilou Gegare Cruz, Mary C. Dundon, John P. Frey, Manjusha Gaglani, Ricardo Grillo Paris, William H. Johnston, Nicola Klein, Tsoline Kojaoghlanian, Paul S. Lei, Colin Marchant, Keith S. Reisinger, Mildred S. Rey, Edward Rothstein, Jack Seidel, Shelly Senders, Steven Shapiro, Peter Silas, Ina Stephens, Lisa Turner, Sylvia Yeh, Ram Yogev.
Novartis study team: Jessica Hackett, Giuseppe Ciavarro, Caitlin McCourt, Marielle Migchelsen, Katherine Lanier, Conor Knightly, Felicia Lipansky, Bridget Waluch, Jina Shah, Cynthia Reeves, Niranjan Kanesa-thasan, Matt Hohenboken.
1. Girard MP, Preziosi MP, Aguado MT, et al.. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692–4700.
2. Rosenstein NE, Perkins BA, Stephens DS, et al.. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis. 1999;180:1894–1901.
3. Thompson MJ, Ninis N, Perera R, et al.. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397–403.
4. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1–21.
5. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
. Lancet. 2007;369:2196–2210.
6. Rennels M, King J Jr, Ryall R, et al.. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2004;23:429–435.
7. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(suppl 2):B51–B63.
8. Cooper B, DeTora L, Stoddard J. Menveo: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines. 2011;10:21–33.
9. Gasparini R, Conversano M, Bona G, et al.. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol. 2010;17:537–544.
10. Reisinger KS, Baxter R, Block SL, et al.. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol. 2009;16:1810–1815.
11. Stamboulian D, Lopardo G, Lopez P, et al.. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis. 2010;14:e868–e875.
12. Arguedas A, Soley C, Loaiza C, et al.. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine. 2010;28:3171–3179.
13. Jackson LA, Baxter R, Reisinger K, et al.. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis. 2009;49:e1–e10.
14. Halperin SA, Gupta A, Jeanfreau R, et al.. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age. Vaccine. 2010;28:7865–7872.
15. Perrett KP, Snape MD, Ford KJ, et al.. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J. 2009;28:186–193.
16. Snape MD, Perrett KP, Ford KJ, et al.. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299:173–184.
17. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307–1326.
18. Granoff DM. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine. 2009;27(suppl 2):B117–B125.
19. Broker M, Dull PM, Rappuoli R, et al.. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine. 2009;27:5574–5580.
Keywords:© 2012 Lippincott Williams & Wilkins, Inc.
meningococcal disease; conjugate vaccine; immunogenicity; safety; infants